Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC

Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are currently lacking. Here, we provide our recommendati...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Liesbeth M. Hondelink, MD, Merel Jebbink, MD, Jan H. von der Thüsen, MD, PhD, Danielle Cohen, MD, PhD, Hendrikus J. Dubbink, PhD, Marthe S. Paats, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Adrianus J. de Langen, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Pieter E. Postmus, MD, PhD, Tom van Wezel, PhD, Kim Monkhorst, MD, PhD
Format: article
Langue:EN
Publié: Elsevier 2021
Sujets:
Non–small cell lung cancer
Molecular diagnostics
Tyrosine kinase inhibitors
Acquired resistance
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Accès en ligne:https://doaj.org/article/15653a46b49e44dca1398d582c62eabe
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/15653a46b49e44dca1398d582c62eabe

Documents similaires